- Home
- SHPH vs TOVX Comparison
SHPH vs TOVX Comparison
Compare SHPH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- TOVX
- Stock Information
- Founded
- SHPH 2012
- TOVX 2001
- Country
- SHPH United States
- TOVX United States
- Employees
- SHPH N/A
- TOVX N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SHPH Health Care
- TOVX Health Care
- Exchange
- SHPH Nasdaq
- TOVX Nasdaq
- Market Cap
- SHPH 3.2M
- TOVX 3.8M
- IPO Year
- SHPH 2022
- TOVX 2006
- Fundamental
- Price
- SHPH $2.55
- TOVX $0.28
- Analyst Decision
- SHPH
- TOVX Hold
- Analyst Count
- SHPH 0
- TOVX 1
- Target Price
- SHPH N/A
- TOVX N/A
- AVG Volume (30 Days)
- SHPH 356.7K
- TOVX 44.2M
- Earning Date
- SHPH 11-13-2025
- TOVX 11-11-2025
- Dividend Yield
- SHPH N/A
- TOVX N/A
- EPS Growth
- SHPH N/A
- TOVX N/A
- EPS
- SHPH N/A
- TOVX N/A
- Revenue
- SHPH N/A
- TOVX N/A
- Revenue This Year
- SHPH N/A
- TOVX N/A
- Revenue Next Year
- SHPH N/A
- TOVX N/A
- P/E Ratio
- SHPH N/A
- TOVX N/A
- Revenue Growth
- SHPH N/A
- TOVX N/A
- 52 Week Low
- SHPH $2.25
- TOVX $0.26
- 52 Week High
- SHPH $30.84
- TOVX $2.08
- Technical
- Relative Strength Index (RSI)
- SHPH 32.85
- TOVX 41.23
- Support Level
- SHPH $2.25
- TOVX $0.26
- Resistance Level
- SHPH $3.56
- TOVX $0.29
- Average True Range (ATR)
- SHPH 0.22
- TOVX 0.06
- MACD
- SHPH -0.06
- TOVX -0.00
- Stochastic Oscillator
- SHPH 21.64
- TOVX 2.19
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.